Life sciences company Revvity (NYSE:RVTY) in Q2 CY2025, with sales up 4.1% year on year to $720.3 million. The company expects the full year’s revenue to be around $2.86 billion, close to analysts’ ...

Life sciences company Revvity (NYSE:RVTY) announced in Q1 CY2025, with sales up 2.3% year on year to $664.8 million. The company’s full-year revenue guidance of $2.85 billion at the midpoint came in 0 ...

Revvity faces multiple headwinds including declining biotech funding, regulatory uncertainty, and reduced academic research budgets. Despite challenges, Revvity's Q1 results beat expectations and the ...

Revvity (NYSE:RVTY) will release its quarterly earnings report on Monday, 2025-04-28. Here's a brief overview for investors ahead of the announcement. Analysts anticipate Revvity to report an earnings ...

Revvity Inc. (NYSE:RVTY) stock is trading lower on Monday following the life science tools maker’s second-quarter 2025 earnings report, which also included a trimmed profit forecast for 2025. The ...

Revvity Inc. (NYSE: RVTY) on Monday reported fourth quarter 2025 adjusted earnings of $1.70 per share, up 19.7% year over year, beating the consensus of $1.55. Adjusted operating income was $229 ...

Revvity (NYSE:RVTY) is preparing to release its quarterly earnings on Monday, 2026-02-02. Here's a brief overview of what investors should keep in mind before the announcement. Analysts expect Revvity ...